A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs NIS 793 (Primary) ; Spartalizumab (Primary)
- Indications Breast cancer; Colorectal cancer; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 22 Feb 2018 Planned End Date changed from 12 Jan 2020 to 13 Jan 2020.
- 22 Feb 2018 Planned primary completion date changed from 12 Jan 2020 to 13 Jan 2020.
- 16 Nov 2017 Planned number of patients changed from 154 to 160.